Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.

导出原文传递

翻译打印收藏纠错

作者： Jin Won,Youn ^[1] ; Soo-Young,Hur ^[2] ; Jung Won,Woo ^[1] ; Yong-Man,Kim ^[3] ; Myong Cheol,Lim ^[4] ; Sang Yoon,Park ^[4] ; Sang Soo,Seo ^[4] ; Jae Hong,No ^[5] ; Byoung-Gie,Kim ^[6] ; Jae-Kwan,Lee ^[7] ; So Jin,Shin ^[8] ; Kyungun,Kim ^[9] ; Marya F,Chaney ^[10] ; Yoon-Jeong,Choi ^[1] ; You Suk,Suh ^[1] ; Jong Sup,Park ^[1] ; Young Chul,Sung ^[11]

作者单位： Genexine, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea. ^[1] The Catholic University of Korea, Seoul St Mary's Hospital, Seocho-gu, Seoul, South Korea. ^[2] Asan Medical Center, Songpa-gu, Seoul, South Korea. ^[3] National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, South Korea. ^[4] Seoul National University Bundang Hospital, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea. ^[5] Samsung Medical Center, Gangnam-gu, Seoul, South Korea. ^[6] Korea University Guro Hospital, Guro-gu, Seoul, South Korea. ^[7] Keimyung University Dongsan Medical Center, Dalseo-gu, Daegu, South Korea. ^[8] National Onco Venture, Ilsandong-gu, Goyang-si, Gyeonggi-do, South Korea. ^[9] Merck & Co, Kenilworth, NJ, USA. ^[10] Genexine, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea; Pohang University of Science and Technology, Pohang, Gyeongbuk, South Korea. Electronic address: ycsung@genexine.com. ^[11]